AbbVie/$ABBV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Ticker
$ABBV
Sector
Primary listing
NYSE
Employees
55,000
Headquarters
Website
AbbVie Metrics
BasicAdvanced
$393B
105.99
$2.10
0.50
$6.47
2.95%
Price and volume
Market cap
$393B
Beta
0.5
52-week high
$225.16
52-week low
$163.81
Average daily volume
4.9M
Dividend rate
$6.47
Financial strength
Current ratio
0.736
Quick ratio
0.48
Long term debt to equity
-45,697.826
Total debt to equity
-51,148.551
Dividend payout ratio (TTM)
301.30%
Interest coverage (TTM)
6.14%
Profitability
EBITDA (TTM)
28,074
Gross margin (TTM)
71.25%
Net profit margin (TTM)
6.45%
Operating margin (TTM)
33.43%
Effective tax rate (TTM)
-24.46%
Revenue per employee (TTM)
$1,060,000
Management effectiveness
Return on assets (TTM)
8.87%
Return on equity (TTM)
112.85%
Valuation
Price to earnings (TTM)
105.987
Price to revenue (TTM)
6.751
Price to book
276.87
Price to tangible book (TTM)
-4.26
Price to free cash flow (TTM)
21.583
Free cash flow yield (TTM)
4.63%
Free cash flow per share (TTM)
10.313
Dividend yield (TTM)
2.91%
Forward dividend yield
2.95%
Growth
Revenue change (TTM)
6.05%
Earnings per share change (TTM)
-29.91%
3-year revenue growth (CAGR)
0.57%
10-year revenue growth (CAGR)
10.76%
3-year earnings per share growth (CAGR)
-33.27%
10-year earnings per share growth (CAGR)
5.02%
3-year dividend per share growth (CAGR)
5.37%
10-year dividend per share growth (CAGR)
12.86%
What the Analysts think about AbbVie
Analyst ratings (Buy, Hold, Sell) for AbbVie stock.
Bulls say / Bears say
AbbVie raised its 2025 profit forecast after Q2 sales of Skyrizi ($4.42 B) and Rinvoq ($2.03 B) exceeded analyst estimates, underscoring the strength of its immunology portfolio. (Reuters)
AbbVie boosted its 2025 EPS guidance to $12.09–$12.29 per share after Q1 Skyrizi ($3.43 B) and Rinvoq ($1.72 B) sales surpassed expectations, demonstrating effective diversification beyond Humira. (Reuters)
The FDA granted accelerated approval in May 2025 for Emrelis (telisotuzumab vedotin) in c-Met overexpressing NSCLC, marking AbbVie’s first approved antibody-drug conjugate in solid tumors and validating its oncology expansion. (Reuters)
Global Humira sales fell to $1.18 B in Q2 2025, missing estimates as biosimilar competition accelerates the erosion of AbbVie’s former top seller. (Reuters)
AbbVie’s Venclexta failed to meet the primary overall survival endpoint in a late-stage myelodysplastic syndrome trial, highlighting challenges in its blood cancer pipeline. (Reuters)
AbbVie cut its 2025 adjusted profit forecast to $11.99–$12.19 per share due to $248 M in acquisition-related expenses, reflecting high integration costs from recent deals. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2025.
AbbVie Financial Performance
Revenues and expenses
AbbVie Earnings Performance
Company profitability
AbbVie News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Oct15
AbbVie
DividendEx-dividend
Nov14
AbbVie
DividendPayment
$1.64Per share
FAQs
What’s the current market cap for AbbVie stock?
AbbVie (ABBV) has a market cap of $393B as of September 23, 2025.
What is the P/E ratio for AbbVie stock?
The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 105.99 as of September 23, 2025.
Does AbbVie stock pay dividends?
Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of September 23, 2025, the dividend rate is $6.47 and the yield is 2.95%. AbbVie has a payout ratio of 301.3% on a trailing twelve-month basis.
When is the next AbbVie dividend payment date?
The next AbbVie (ABBV) dividend payment is scheduled for November 14, 2025.
What is the beta indicator for AbbVie?
AbbVie (ABBV) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.